Health
Novavax Covid vaccine highly effective, but not against S.Africa variant – Yahoo News Australia
US biotech firm Novavax said Thursday its two-shot Covid-19 vaccine showed an overall efficacy of 89.3 percent in a major Phase 3 clinical trial in Britain, …
US biotech firm Novavax said Thursday its two-shot Covid-19 vaccine showed an overall efficacy of 89.3 percent in a major Phase 3 clinical trial in Britain, and remained highly effective against a variant first identified there.
But the positive news was partly offset by other results that showed it offered significantly less protection against a highly transmissible variant of the coronavirus first identified in South Africa, which is spreading rapidly around the world.
Novavax said it began working…
-
Noosa News16 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News17 hours agoMotorcyclist dies in crash with truck
-
Noosa News18 hours agoSomerville House investigating after teachers’ dossier on students leaked
-
General23 hours agoSmall-town cleaner finds himself in legal battle with EnduroShield over product packaging
